<?xml version="1.0" encoding="UTF-8"?>
<p>Another approach for treatment of COVID-19 is to use a soluble form of ACE2. A recombinant human ACE2 (rhACE2; APN01, and GSK2586881) is safe in patients with acute respiratory distress syndrome [
 <xref rid="B134-pharmaceuticals-13-00096" ref-type="bibr">134</xref>,
 <xref rid="B135-pharmaceuticals-13-00096" ref-type="bibr">135</xref>]. Treatment with rhACE2 rapidly abolishes the elevated levels angiotensin-II, with a trend to decrease the plasma concentration of IL-6. A small clinical trial of rhACE2 in patients with severe SARS-CoV-2 infection was recently initiated (NCT04287686).
</p>
